PEN - Penumbra, Inc.

NYSE - NYSE Delayed Price. Currency in USD

Penumbra, Inc.

One Penumbra Place
1351 Harbor Bay Parkway
Alameda, CA 94502
United States
510-748-3200
http://www.penumbrainc.com

Sector
Industry
Full Time Employees1,500

Key Executives

NameTitlePayExercisedAge
Mr. Adam ElsesserCo Founder, Chairman, Chief Exec. Officer and Pres726.91k14M55
Dr. Arani Bose M.D.Co-Founder, Chief Innovator and Director501.91k14M55
Mr. Sridhar N. KosarajuChief Financial Officer and Head of Strategy501.91kN/A39
Ms. Lynn RothmanChief Bus. Officer and Exec. VP503.86kN/A56
Mr. Daniel Donen DavisChief Commercial Officer & Pres of North America502.2kN/A39
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, PX SLIM, and Velocity brands; aspiration based thrombectomy systems and accessory devices under the Penumbra System brand; and revascularization device for mechanical thrombectomy under the 3D brand. It also provides neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands; and neurovascular stents for stent-assisted coiling in large and wide-neck aneurysms under the LIBERTY Stent brand. In addition, the company offers neurosurgical aspiration tools for the removal of tissue and fluids under the Apollo System brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the Lantern brand. Further, it provides detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (penumbra occlusion device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as POD Packing Coil, a device for use with RUBY Coil and POD for vessel occlusion. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Corporate Governance

Penumbra, Inc.’s ISS Governance QualityScore as of November 1, 2017 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.